Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in Relapsed EGFR-mutated NSCLC
NCT02504346Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Aug 2015
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02504346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504346.